Rothschild, S

Up a level
Export as [feed] RSS
Group by: Item Type | No Grouping
Number of items: 6.

Journal Article

Jörger Messerli, Marianne; Baty, F; Früh, M; Stahel, R A; Betticher, D C; von Moos, Rodica; Ochsenbein, Adrian; Pless, M; Gautschi, O; Rothschild, S; Brauchli, P; Klingbiel, Dirk; Zappa, F; Brutsche, M (2014). Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05). Lung cancer, 85(2), pp. 306-313. Elsevier 10.1016/j.lungcan.2014.04.014

Book Section

Rothschild, S; Gautschi, O (2010). KRAS bei anderen Tumoren. In: Bremen et al.: UNI-MED

Rothschild, S; Betticher, D; Ochsenbein, A; Stahel, R; Bubendorf L.Gugger, M.; Brutsche, M; Pless, M; Gautschi, O (2010). Bedeutung der Histologie für die Therapie des fortgeschrittenen, nicht-kleinzelligen Bronchuskarzinoms. In: Swiss Med Forum

Rothschild, S; Gautschi, O (2010). NSCLC bei Patienten in reduziertem Allgemeinzustand: Mehr oder weniger Chemotherapie? In: Leading Opinions Hämatologie & Onkologie

Rothschild, S; Gautschi, O (2010). Die molekulare Behandlung des Kolonkarzinoms. In: Schweizer Zeitschrift für Onkologie

Conference or Workshop Item

Rothschild, S; Amrein, Michael; Riether, Carsten; Gautschi, O; Schuster, N; Li, Q; Savic, S; Schneider, M; Biaggi, C; Bubendorf, L; Brutsche, M; Zippelius, A; Zander, T; Betticher, D; Früh, M; Stahel, R; Cathomas, R; Rauch, Daniel; Pless, M; Ochsenbein, Adrian; ... (October 2017). CCNE1, PTGS2, TGFA and WISP2 Predict Benefit from Bevacizumab and Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer (SAKK19/09). Journal of thoracic oncology, 12(11S2), S1864-S1865. Elsevier

This list was generated on Thu Mar 28 13:13:10 2024 CET.
Provide Feedback